Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center
Advertisement
Articles by Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center
Advertisement
Latest Updated Articles
PI3KCA Inhibition: Managing AEs in HR+ mBCPublished: July 21st 2021 | Updated:
Early Stage HR+ Breast Cancer: Optimizing Multigene AssaysPublished: August 4th 2021 | Updated:
Using Genomic Assays for Early Stage HR+ Breast CancerPublished: July 28th 2021 | Updated:
ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical PracticePublished: August 11th 2021 | Updated:
Emerging Agents for the Management of HR+ mBCPublished: July 28th 2021 | Updated:
Using CDK4/6 Inhibitors After HR+ mBC Disease ProgressionPublished: July 21st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5